Viral Hepatitis: Historical Perspectives from the 20th to the 21st Century

Archives of Medical Research

Volumn 38, Issue 6, 2007, Pages 593-605

  Pérez, Victor ^a  

^a Instituto Argentino de Diagnostico y Tratamiento   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; ANTIVIRUS AGENT; CYTOKINE; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; INTERFERON; INTERLEUKIN 6; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; RECOMBINANT VACCINE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; THYMOSIN ALPHA1;

DELTA AGENT HEPATITIS; DISEASE COURSE; DISEASE MARKER; DISEASE TRANSMISSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEMOLYSIS; HEPATITIS; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS E; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; LIVER TRANSPLANTATION; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OPEN READING FRAME; PASSIVE IMMUNIZATION; REVIEW; SEXUAL TRANSMISSION; VERTICAL TRANSMISSION; VIRAL GENETICS; VIRUS HEPATITIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS VIRUSES; HEPATITIS, VIRAL, HUMAN; HISTORY, 20TH CENTURY; HUMANS; INTERFERONS; MALE; NUCLEIC ACID SYNTHESIS INHIBITORS; VIRAL HEPATITIS VACCINES;

EID: 34347209893     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.09.020     Document Type: Review

References (131)

1. Payen J.L., and Rongieres M. Histoire des hepatites 1. De la jaunisse au virus. La Revue du Praticien (2002), France, Toulouse 2097-2100
2. Payen J.L., and Rongieres M. Histoire des hepatites 2. Individualisation de l'hepatite epidemique et grandes hyoptheses pathogeniques. La Revue du Praticien (2002), France, Toulouse 2213-2217
3. Payen J.L., and Rongieres M. Histoire des hepatites 3. L'ere des antigenes et de la microscopie electronique. La Revue du Praticien (2003), France, Toulouse 7-10
4. Payen JL, Rongieres M, Histoire des hepatites 4. Le miracle de la biologie moleculaire: la decouverte des virus des hepatites C et E. In: La Revue du Praticien: Buenos Aires, Argentina; 2003. pp. 123-126.
5. Virchow R. Ueber das Vorkommen und den Nachweis des hepatogenen, insbesondere des katarrhalischen Ikterus. Arch Pathol Anat 32 (1865) 117
6. Lurman. Eine Ikterusepidemie. Berlin Klin Wschr 22 (1885) 20-23
7. Jehn. Eine Ikterusepidemie in wahrscheinlichem. Zusammenhang mit vorausgegangener Revaccination. Dtsch Med Wochenschr 11 (1885) 339
8. Flaum A.M.H., Malmoros H., and Persson E. Eine nosocomiale Ikterusepidemie. Acta Med Scand 16 Suppl (1926) 544-553
9. Stokes J.H., Ruedermann R., and Lemon W.S. Epidemic infectious jaundice and its relation to the therapy of syphilis. Arch Intern Med 26 (1920) 521-543
10. Sherwood P.M. An outbreak of syringe transmitted hepatitis with jaundice in hospitalized diabetic patients. Ann Intern Med 33 (1950) 380-396
11. MacCallum F.O. Early studies of viral hepatitis. Br Med Bull 28 (1972) 105-108
12. Schmid R. History of viral hepatitis: a tale of dogmas and misinterpretations. J Gastroenterol Hepatol 16 (2001) 718-722
13. Editorial. Jaundice following yellow fever vaccination. JAMA 119 (1942) 1110
14. McDonald S. Acute yellow atrophy. Edinb Med J 15 (1908) 208
15. Murray R. Viral hepatitis. Bull NY Acad Med 31 (1955) 341-358
16. Schaffner F. The history of liver disease at The Mount Sinai Hospital. Mt Sinai J Med 67 (2000) 76-83
17. Provost P.J., and Hilleman M.R. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 160 (1979) 213-221
18. Deinhardt F., Holmes A.W., Capps R.B., and Popper H. Studies on the transmission of human viral hepatitis to marmoset monkeys. I. Transmission of disease, serial passages, and description of liver lesions. J Exp Med 125 (1967) 673-688
19. Provost P.J., and Hilleman M.R. An inactivated hepatitis A virus vaccine prepared from infected marmoset liver. Proc Soc Exp Biol Med 159 (1978) 201-203
20. Krugman S. The Willowbrook hepatitis studies revisited: ethical aspects. Rev Infect Dis 8 (1986) 157-162
21. Krugman S., Giles J.P., and Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 200 (1967) 365-673
22. Krugman S., and Gocke D.J. Viral hepatitis. Major Probl Intern Med 15 (1978) 1-147
23. Boggs J.D., Melnick J.L., Conrad M.E., and Felsher B.F. Viral hepatitis. Clinical and tissue culture studies. JAMA 214 (1970) 1041-1046
24. Feinstone S.M., Kapikian A.Z., and Purceli R.H. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182 (1973) 1026-1028
25. Koff R.S., Feinstone S.M., Kapikian A.Z., and Purcell R.H. Hepatitis A: detection by immune electron microscopy of a virus like antigen associated with acute illness. [Science 1973;182:1026-1028]. J Hepatol 37 (2002) 2-6
26. Hollinger F.B., Bradley D.W., Maynard J.E., Dreesman G.R., and Melnick J.L. Detection of hepatitis A viral antigen by radioimmunoassay. J Immunol 115 (1975) 1464-1466
27. Hollinger F.B., Dienstag J.L., and Swenson P.D. Hepatitis viruses. In: Balows A., Hausler Jr. W.J., Herrmann K.L., et al. (Eds). Manual of Clinical Microbiology (1991), American Society for Microbiology, Washington, DC 959-983
28. Hollinger F.B., and Emerson S.U. Hepatitis A virus. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia, PA 799-840
29. Dienstag J.L., Feinstone S.M., Purcell R.H., Hoofnagle J.H., Barker L.F., London W.T., et al. Experimental infection of chimpanzees with hepatitis A virus. J Infect Dis 132 (1975) 532-545
30. Maynard J.E., Bradley D.W., Gravelle C.R., Ebert J.W., and Krushak D.H. Preliminary studies of hepatitis A in chimpanzees. J Infect Dis 131 (1975) 194-197
31. Blumberg B.S., Alter H.J., and Visnich S. A new antigen in leukemia sera. JAMA 191 (1965) 541-546
32. Blumberg B.S. Australia antigen and the biology of hepatitis B. Science 197 (1977) 17-25
33. Blumberg B.S., Gerstley B.J., Hungerford D.A., London W.T., and Sutnick A.I. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 66 (1967) 924-931
34. Prince A.M. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci USA 60 (1968) 814-821
35. Dane D.S., Cameron C.H., and Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1 (1970) 695-698
36. Prince A.M., and Brotman B. Perspectives on hepatitis B studies with chimpanzees. Ilar J 42 (2001) 85-88
37. Gripon P., Diot C., Theze N., Fourel I., Loreal O., Brechot C., et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 62 (1988) 4136-4143
38. Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99 (2002) 15655-15660
39. Glebe D., Aliakbari M., Krass P., Knoop E.V., Valerius K.P., and Gerlich W.H. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 77 (2003) 9511-9521
40. Acs G., Sells M.A., Purcell R.H., Price P., Engle R., Shapiro M., et al. Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci USA 84 (1987) 4641-4644
41. Ganem D., and Schneider R.J. Hepadnaviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia, PA 2923-2969
42. Hollinger F.B., and Liang T.J. Hepatitis B virus. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadephia, PA 2971-3036
43. Ou J.H., Laub O., and Rutter W.J. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci USA 83 (1986) 1578-1582
44. Carman W.F., Fagan E.A., Hadziyannis S., Karayiannis P., Tassopoulos N.C., Williams R., et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 14 (1991) 219-222
45. Popper H., Shafritz D.A., and Hoofnagle J.H. Relation of the hepatitis B virus carrier state to hepatocellular carcinoma. Hepatology 7 (1987) 764-772
46. Menghini G. One-second needle biopsy of the liver. Gastroenterology 35 (1958) 190-199
47. Shafritz D.A., Shouval D., Sherman H.I., Hadziyannis S.J., and Kew M.C. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 305 (1981) 1067-1073
48. Laurent-Puig P., and Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 25 (2006) 3778-3786
49. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25 (2006) 3834-3847
50. Krugman S., Giles J.P., and Hammond J. Hepatitis virus: effect of heat on the infectivity and antigenicity of the MS-1 and MS-2 strains. J Infect Dis 122 (1970) 432-436
51. Krugman S., Giles J.P., and Hammond J. Viral hepatitis, type B (MS-2 strain). Studies on active immunization. JAMA 217 (1971) 41-45
52. Blumberg BS, Millman I. Vaccine against viral hepatitis and process. U.S. Patent Office No. 3-636-191, 1972.
53. Hilleman M.R. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 18 (2000) 1436-1447
54. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303 (1980) 833-841
55. Szmuness W., Stevens C.E., Zang E.A., Harley E.J., and Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1 (1981) 377-385
56. Valenzuela P., Medina A., Rutter W.J., Ammerer G., and Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298 (1982) 347-350
57. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., and Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 307 (1984) 178-180
58. Muraskin W. The War Against Hepatitis B. A History of the International Task Force on Hepatitis B Immunization (1995), University of Pennsylvania Press, Philadelphia, PA
59. Lok A.S. The maze of treatments for hepatitis B. N Engl J Med 352 (2005) 2743-2746
60. Craxi A., and Yurdaydin C. From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005). J Hepatol 44 (2006) 1186-1195
61. Craxi A., Antonucci G., and Camma C. Treatment options in HBV. J Hepatol 44 1 Suppl (2006) S77-S83
62. Perez V., Tanno H., and Barclay C.A. Treatment of chronic hepatitis B with recombinant interferon alpha. In: Zuckerman A.J. (Ed). Viral Hepatitis and Liver Disease (1988), Alan R. Liss, New York, NY
63. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
64. Xu X.W., and Chen Y.G. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 5 (2006) 350-359
65. Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24 (1996) 711-713
66. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., and Tyrrell D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24 (1996) 714-717
67. Lai C.L., Dienstag J., Schiff E., Leung N.W., Atkins M., Hunt C., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
68. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
69. Schiff E.R., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38 (2003) 1419-1427
70. Zeng M., Mao Y., Yao G., Wang H., Hou J., Wang Y., et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 44 (2006) 108-116
71. de Man R.A., Wolters L.M., Nevens F., Chua D., Sherman M., Lai C.L., et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34 (2001) 578-582
72. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F., et al. Entervir resistance is rare in nucleoside naive patients with hepatitis B. Hepatolology 44 (2006) 1656-1665
73. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
74. Chien R.N., Liaw Y.F., Chen T.C., Yeh C.T., and Sheen I.S. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 27 (1998) 1383-1387
75. Iino S., Iino S., Toyota J., Kumada H., Kiyosawa K., Kakumu S., Sata M., et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B: results from a randomized clinical trial. J Viral Hepat 12 (2005) 300-306
76. Rizzetto M., Canese M.G., Arico S., Crivelli O., Trepo C., Bonino F., et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 18 (1977) 997-1003
77. Rizzetto M. The delta agent. Hepatology 3 (1983) 729-737
78. Rizzetto M., Hoyer B., Canese M.G., Shih J.W., Purcell R.H., and Gerin J.L. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci USA 77 (1980) 6124-6128
79. Alter H. Discovery of non-A, non-B hepatitis and identification of its etiology. Am J Med 107 (1999) 16S-120S
80. Alter M.J., and Mast E.E. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 23 (1994) 437-455
81. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
82. Lindenbach B.D., and Rice C.M. Flaviviridae: The viruses and their replication. In: Howley P.M., David M., and Knipe D.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia, PA 991-1041
83. Major M.E., Rehermann B., and Feinstone S.M. Hepatitis C viruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia, PA 1127-1161
84. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85 (2004) 3173-3188
85. Simmonds P. Variability of hepatitis C virus. Hepatology 21 (1995) 570-583
86. Irving W.L. Acute hepatitis C virus infection: a neglected disease?. Gut 55 (2006) 1075-1077
87. Dienstag J.L. Hepatitis C: a bitter harvest. Ann Intern Med 144 (2006) 770-771
88. Cacoub P., Saadoun D., Limal N., Sene D., Lidove O., and Piette J.C. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52 (2005) 911-915
89. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 5 Suppl. 1 (2004) S27-S34
90. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
91. Donahue J.G., Munoz A., Ness P.M., Brown Jr. D.E., Yawn D.H., McAllister Jr. H.A., et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327 (1992) 369-373
92. Hayashi N., and Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 41 (2006) 17-27
93. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
94. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 (2005) 2609-2617
95. von Wagner M., Huber M., Berg T., Hinrichsen H., Rasenack J., Heintges T., et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129 (2005) 522-527
96. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
97. Zanetti A.R., Tanzi E., Romano L., Zuin G., Minola E., Vecchi L., et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 41 (1998) 208-212
98. Zylberberg H., Thiers V., Lagorce D., Squadrito G., Leone F., Berthelot P., et al. Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut 45 (1999) 112-116
99. Zignego A.L., Ferri C., Pileri S.A., Caini P., and Bianchi F.B. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 39 (2007) 2-17
100. Blackard J.T., Kemmer N., and Sherman K.E. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 44 (2006) 15-22
101. Bonkovsky H.L., Poh-Fitzpatrick M., Pimstone N., Obando J., Di Bisceglie A., Tattrie C., et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 27 (1998) 1661-1669
102. Czaja A.J. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis 15 (1997) 125-144
103. Duberg A.S., Nordstrom M., Torner A., Reichard O., Strauss R., Janzon R., et al. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 4 (2005) 652-659
104. Lunel F., and Musset L. Hepatitis C virus infection and cryoglobulinemia. J Hepatol 29 (1998) 848-855
105. Mayo M.J. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 325 (2003) 135-148
106. Sulkowski M.S., Moore R.D., Mehta S.H., Chaisson R.E., and Thomas D.L. Hepatitis C and progression of HIV disease. JAMA 288 (2002) 199-206
107. Benhamou Y., Bochet M., Di Martino V., Charlotte F., Azria F., Coutellier A., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30 (1999) 1054-1058
108. Cribier B., Rey D., Schmitt C., Lang J.M., Kirn A., and Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. Aids 9 (1995) 1131-1136
109. Thio C. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 23 (2003) 125-136
110. Khuroo M.S. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 68 (1980) 818-824
111. Wong D.C., Purcell R.H., Sreenivasan M.A., Prasad S.R., and Pavri K.M. Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet 2 (1980) 876-879
112. Balayan M.S., Andjaparidze A.G., Savinskaya S.S., Ketiladze E.S., Braginsky D.M., Savinov A.P., et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 20 (1983) 23-31
113. Bradley D.W. Enterically-transmitted non-A, non-B hepatitis. Br Med Bull 46 (1990) 442-461
114. Emerson S.U., and Purcell R.H. Hepatitis E virus. Rev Med Virol 13 (2003) 145-154
115. Li T.C., Yamakawa Y., Suzuki K., Tatsumi M., Razak M.A., Uchida T., et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 71 (1997) 7207-7213
116. Purcell R.H., and Emerson S.U. Animal models of hepatitis A and E. Ilar J 42 (2001) 161-177
117. Emerson S.U., Nguyen H., Torian U., and Purcell R.H. ORF3 protein of hepatitis E virus is not required for replication, virion assembly or infection of hepatoma cells in vitro. J Virol 80 (2006) 10457-10464
118. Karayiannis P., and McGarvey M.J. The GB hepatitis viruses. J Viral Hepat 2 (1995) 221-226
119. Linnen J., Wages Jr. J., Zhang-Keck Z.Y., Fry K.E., Krawczynski K.Z., Alter H., et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 271 (1996) 505-508
120. Stapleton J.T. GB virus type C/hepatitis G virus. Semin Liver Dis 23 (2003) 137-148
121. Wang J.T., Tsai F.C., Lee C.Z., Chen P.J., Sheu J.C., Wang T.H., et al. A prospective study of transfusion-transmitted GB virus C infection: similar frequency but different clinical presentation compared with hepatitis C virus. Blood 88 (1996) 1881-1886
122. Jarvis L.M., Davidson F., Hanley J.P., Yap P.L., Ludlam C.A., and Simmonds P. Infection with hepatitis G virus among recipients of plasma products. Lancet 348 (1996) 1352-1355
123. Thomas D.L., Vlahov D., Alter H.J., Hunt J.C., Marshall R., Astemborski J., et al. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis 177 (1998) 539-542
124. Scallan M.F., Clutterbuck D., Jarvis L.M., Scott G.R., and Simmonds P. Sexual transmission of GB virus C/hepatitis G virus. J Med Virol 55 (1998) 203-208
125. Feucht H.H., Zollner B., Polywka S., and Laufs R. Vertical transmission of hepatitis G. Lancet 347 (1996) 615-616
126. Simons J.N., Desai S.M., and Mushahwar I.K. The GB viruses. Curr Top Microbiol Immunol 242 (2000) 341-375
127. Han Y.S., Lee S.K., Joh J.W., Kim S.J., Kwon C.H., Park J.W., et al. Outcomes of hepatitis B virus recurrence after liver transplantation. Transplant Proc 38 (2006) 2123-2124
128. Wiesner R.H., Sorrell M., and Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 9 (2003) S1-S9
129. Garcia-Retortillo M., Forns X., Feliu A., Moitinho E., Costa J., Navasa M., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35 (2002) 680-687
130. Powers K.A., Ribeiro R.M., Patel K., Pianko S., Nyberg L., Pockros P., et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 12 (2006) 207-216
131. Schreibman I.R., and Schiff E.R. Prevention and treatment of recurrent hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 5 (2006) 8